George D Demetri Selected Research

Liposarcoma

12/2019	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
1/2019	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
10/2017	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
1/2017	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
4/2016	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
3/2016	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
3/2016	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
9/2014	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
2/2012	Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
9/2011	Aberrant AKT activation drives well-differentiated liposarcoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George D Demetri Research Topics

Disease

98	Neoplasms (Cancer) 05/2022 - 01/2002
61	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2021 - 01/2002
43	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 02/2002
22	Disease Progression 01/2021 - 10/2002
14	Liposarcoma 12/2019 - 09/2002
12	Leiomyosarcoma 12/2019 - 09/2009
11	Fatigue 01/2016 - 04/2002
8	Anemia 01/2017 - 02/2002
7	Nausea 01/2016 - 10/2006
7	Hypertension (High Blood Pressure) 08/2014 - 12/2007
7	Breast Neoplasms (Breast Cancer) 05/2008 - 03/2002
6	Thrombocytopenia (Thrombopenia) 01/2021 - 11/2002
6	Neutropenia 05/2015 - 05/2002
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 09/2002
4	Neoplasm Metastasis (Metastasis) 01/2018 - 07/2012
4	Cardiotoxicity 01/2016 - 05/2002
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 08/2002
4	Renal Cell Carcinoma (Grawitz Tumor) 12/2012 - 11/2006
4	Lung Neoplasms (Lung Cancer) 03/2012 - 02/2002
3	Alveolar Soft Part Sarcoma 03/2016 - 12/2012
3	Vomiting 01/2016 - 06/2012
3	Genetic Translocation (Chromosomal Translocation) 07/2015 - 07/2007
3	Melanoma (Melanoma, Malignant) 09/2013 - 04/2008
3	Leukemia 10/2009 - 06/2003
3	Dermatofibrosarcoma 05/2008 - 02/2005
2	Rare Diseases (Rare Disease) 01/2022 - 09/2003
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2004
2	Synovial Sarcoma (Synovioma) 11/2019 - 10/2019
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2018 - 11/2009
2	Clear Cell Sarcoma 07/2015 - 12/2012
2	Abdominal Pain (Pain, Abdominal) 05/2015 - 03/2009
2	Stomatitis 06/2014 - 07/2013
2	Diarrhea 06/2014 - 08/2002
2	Exanthema (Rash) 06/2014 - 07/2013
2	Weight Loss (Weight Reduction) 06/2014 - 05/2012
2	Myxoid Liposarcoma 11/2012 - 07/2007
2	Edema (Dropsy) 11/2012 - 08/2002
2	Alopecia (Baldness) 03/2012 - 05/2002
2	Aggressive Fibromatosis (Desmoid) 05/2008 - 03/2006

Drug/Important Bio-Agent (IBA)

58	Imatinib Mesylate (Gleevec)FDA Link 12/2019 - 08/2002
31	Phosphotransferases (Kinase)IBA 01/2022 - 01/2003
20	Sunitinib (Sutent)FDA Link 12/2019 - 11/2006
15	Tyrosine Kinase InhibitorsIBA 01/2021 - 08/2002
15	Pharmaceutical PreparationsIBA 01/2021 - 10/2002
14	TrabectedinIBA 01/2021 - 01/2002
10	Biological ProductsIBA 03/2020 - 06/2003
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2003
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 08/2002
7	Dacarbazine (DIC)FDA LinkGeneric 12/2019 - 03/2016
7	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2016 - 12/2003
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2021 - 09/2002
6	regorafenibIBA 01/2021 - 07/2012
6	AnthracyclinesIBA 01/2017 - 02/2002
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2009
5	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2015 - 02/2002
5	Oncogene Proteins (Oncogene Protein)IBA 11/2012 - 01/2003
4	tyrosine receptor (receptor, tyrosine)IBA 01/2019 - 07/2013
4	Erythropoietin FDA Link 01/2005 - 02/2002
4	Epoetin Alfa (Epogen)FDA Link 08/2002 - 01/2002
3	entrectinibIBA 05/2022 - 01/2021
3	TropomyosinIBA 01/2022 - 01/2018
3	larotrectinibIBA 03/2020 - 01/2018
3	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2017
3	Angiogenesis InhibitorsIBA 05/2012 - 09/2004
3	Tyrosine (L-Tyrosine)FDA Link 04/2012 - 04/2004
3	Sorafenib (BAY 43-9006)FDA Link 02/2012 - 02/2008
3	thiamine triphosphorate (TTP)IBA 07/2010 - 11/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2008 - 03/2002
3	Hemoglobins (Hemoglobin)IBA 01/2005 - 08/2002
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 03/2020
2	Gemcitabine FDA Link 01/2021 - 05/2007
2	Therapeutic UsesIBA 01/2020 - 06/2003
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2019 - 10/2019
2	pazopanib FDA Link 08/2019 - 05/2012
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2012
2	eribulin FDA Link 10/2017 - 04/2016
2	Microphthalmia-Associated Transcription FactorIBA 07/2015 - 12/2012
2	CytokinesIBA 07/2015 - 11/2002
2	nilotinib FDA Link 05/2015 - 09/2009
2	Ifosfamide FDA LinkGeneric 05/2015 - 09/2009
2	Tumor Biomarkers (Tumor Markers)IBA 09/2014 - 06/2003
2	Small Interfering RNA (siRNA)IBA 09/2014 - 07/2013
2	Protein Isoforms (Isoforms)IBA 06/2014 - 12/2003
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2013 - 09/2006
2	TOR Serine-Threonine KinasesIBA 07/2013 - 01/2012
2	ridaforolimusIBA 07/2013 - 01/2012
2	Transaminases (Aminotransferases)IBA 06/2012 - 05/2002
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2008 - 11/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2008 - 03/2003
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2007 - 06/2005
2	Semaxinib (SU5416)IBA 01/2005 - 09/2004
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2005 - 09/2004
2	Troglitazone (Rezulin)FDA Link 06/2003 - 09/2002

Therapy/Procedure

69	Therapeutics 01/2022 - 01/2002
25	Drug Therapy (Chemotherapy) 12/2019 - 01/2002
4	Intravenous Infusions 05/2015 - 10/2002
3	Immunotherapy 11/2019 - 01/2017
2	Aftercare (After-Treatment) 07/2012 - 05/2006
2	Radiotherapy 04/2012 - 01/2008
2	Adjuvant Chemotherapy 05/2008 - 03/2003